MA32938B1 - Composes organiques - Google Patents

Composes organiques

Info

Publication number
MA32938B1
MA32938B1 MA33969A MA33969A MA32938B1 MA 32938 B1 MA32938 B1 MA 32938B1 MA 33969 A MA33969 A MA 33969A MA 33969 A MA33969 A MA 33969A MA 32938 B1 MA32938 B1 MA 32938B1
Authority
MA
Morocco
Prior art keywords
organic compounds
compounds
organic
subject
Prior art date
Application number
MA33969A
Other languages
Arabic (ar)
English (en)
Inventor
Jun Zhao
Hailin Zeng
Peng Li
Lawrence P Wennogle
Original Assignee
Intra Cellular Therapies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42233533&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA32938(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intra Cellular Therapies Inc filed Critical Intra Cellular Therapies Inc
Publication of MA32938B1 publication Critical patent/MA32938B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/529—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Abstract

3-(THIO, SULFINYL OU SULFONYL)-7,8-DIHYDRO-(1H OU 2H)-IMIDAZO[1,2-A]PYRAZOLO[4,3-E]PYRIMIDIN-4(5H)-ONES ÉVENTUELLEMENT SUBSTITUÉES, 3-(THIO, SULFINYL OU SULFONYL)-7,8,9-TRIHYDRO'(1H OU 2H)-PYRIMIDO[1,2-A]PYRAZOLO[4,3-E]PYRIMIDIN-4(5?)-ONES OU COMPOSÉS DE FORMULE (I), LEURS PROCÉDÉS DE PRODUCTION, LEUR EMPLOI EN TANT QUE PRODUITS PHARMACEUTIQUES ET LES COMPOSITIONS PHARMACEUTIQUES LES INCLUANT.
MA33969A 2008-12-06 2009-12-07 Composes organiques MA32938B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12044208P 2008-12-06 2008-12-06
PCT/US2009/006439 WO2010065149A1 (fr) 2008-12-06 2009-12-07 Composés organiques

Publications (1)

Publication Number Publication Date
MA32938B1 true MA32938B1 (fr) 2012-01-02

Family

ID=42233533

Family Applications (1)

Application Number Title Priority Date Filing Date
MA33969A MA32938B1 (fr) 2008-12-06 2009-12-07 Composes organiques

Country Status (23)

Country Link
US (4) US8536159B2 (fr)
EP (1) EP2367429B1 (fr)
JP (1) JP5778582B2 (fr)
KR (1) KR20110095881A (fr)
CN (1) CN102231953A (fr)
AU (1) AU2009322901A1 (fr)
BR (1) BRPI0922348A2 (fr)
CA (1) CA2740391A1 (fr)
CL (1) CL2011001263A1 (fr)
CO (1) CO6390083A2 (fr)
CR (1) CR20110312A (fr)
DO (1) DOP2011000173A (fr)
EA (1) EA201170770A1 (fr)
EC (1) ECSP11011184A (fr)
ES (1) ES2638912T3 (fr)
IL (1) IL213314A0 (fr)
MA (1) MA32938B1 (fr)
MX (1) MX2011005933A (fr)
PE (1) PE20110922A1 (fr)
SG (1) SG171775A1 (fr)
TN (1) TN2011000246A1 (fr)
WO (1) WO2010065149A1 (fr)
ZA (1) ZA201103631B (fr)

Families Citing this family (56)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20140022114A (ko) 2005-06-06 2014-02-21 다케다 야쿠힌 고교 가부시키가이샤 유기 화합물
AU2007256633B2 (en) 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
EP2081431B1 (fr) * 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Composés organiques
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
WO2009073210A1 (fr) * 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Composés organiques
EP2240490B1 (fr) * 2007-12-06 2013-09-04 Takeda Pharmaceutical Company Limited Composés organiques
EP2358204B1 (fr) * 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. Composés de 4,5,7,8-tétrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine comme inhibiteurs de PDE1.
SG171775A1 (en) * 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
JP5813511B2 (ja) 2008-12-06 2015-11-17 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EA201170773A1 (ru) 2008-12-06 2012-01-30 Интра-Селлулар Терапиз, Инк. Органические соединения
PE20120209A1 (es) 2008-12-06 2012-03-18 Intra Cellular Therapies Inc DERIVADOS DE IMIDAZO-[1,2-a]-PIRAZOLO [4,3-e]PIRIMIDINA O PIRIMIDO-[1,2-a]-PIRAZOLO [4,3-e]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1)
PE20110834A1 (es) 2008-12-06 2011-12-14 Intra Cellular Therapies Inc DERIVADOS DE PIRROL[3,4-d]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1)
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
JP2013507360A (ja) * 2009-10-08 2013-03-04 イントラ−セルラー・セラピーズ・インコーポレイテッド ホスホジエステラーゼ１−標的トレーサーおよび方法
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP5911854B2 (ja) 2010-05-31 2016-04-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP6051210B2 (ja) * 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
HUE055562T2 (hu) 2011-11-23 2021-11-29 Therapeuticsmd Inc Természetes kombinációjú hormon helyettesítõ kiszerelések, és terápiák ezekkel
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
MX357320B (es) 2012-06-18 2018-07-04 Dart Neuroscience Cayman Ltd Compuestos de la azolopirimidina-5-(6h)-ona de piridina sustituida.
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
AR091507A1 (es) 2012-06-21 2015-02-11 Intra Cellular Therapies Inc SALES DE (6aR,9aS)-5,6a,7,8,9,9a-HEXAHIDRO-5-METIL-3-(FENILAMINO)-2-((4-(6-FLUOROPIRIDIN-2-IL)FENIL)METIL)-CICLOPENT[4,5]IMIDAZO[1,2-a]PIRAZOLO[4,3-e]PIRIMIDIN-4(2H)-ONA
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
US9073936B2 (en) 2013-03-15 2015-07-07 Intra-Cellular Therapies, Inc. Organic compounds
ES2717688T3 (es) 2013-03-15 2019-06-24 Intra Cellular Therapies Inc Inhibidores de la PDE1 para uso en el tratamiento y/o prevención de lesiones de SNC, y enfermedades, trastornos o lesiones de SNP
CN110498800A (zh) * 2013-06-21 2019-11-26 细胞内治疗公司 游离碱晶体
JP6696904B2 (ja) 2014-01-08 2020-05-20 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 製剤および医薬組成物
EP3145489A1 (fr) 2014-05-22 2017-03-29 TherapeuticsMD, Inc. Formulations d'hormones substitutives combinées naturelles et traitement hormonal substitutif
US9884872B2 (en) 2014-06-20 2018-02-06 Intra-Cellular Therapies, Inc. Organic compounds
AU2015296609A1 (en) 2014-07-29 2016-12-22 Therapeuticsmd, Inc. Transdermal cream
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
DK3177627T3 (da) 2014-08-07 2019-10-21 Intra Cellular Therapies Inc Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-on-derivater med pde1-hæmmende aktivitet
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
EP3725789B1 (fr) 2014-09-17 2022-03-09 Intra-Cellular Therapies, Inc. Dérivés de 7,8-dihydro-[2h]-imidazo-[1,2-a]pyrazolo[4,3-e]pyrimidin-4(5h)-one en tant qu'inhibiteurs de phosphodiestérase 1 (pde1) pour le traitement de maladies, troubles ou blessures du sytème nerveux central (snc)
JP6608934B2 (ja) 2014-12-06 2019-11-20 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
JP6608933B2 (ja) 2014-12-06 2019-11-20 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
JP2019510039A (ja) 2016-03-28 2019-04-11 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規組成物および方法
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
ES2906107T3 (es) 2016-09-12 2022-04-13 Intra Cellular Therapies Inc Usos novedosos
WO2019152697A1 (fr) 2018-01-31 2019-08-08 Intra-Cellular Therapies, Inc. Nouvelles utilisations
US11628171B2 (en) 2019-03-13 2023-04-18 Children's Medical Center Corporation Method for treating brain or nerve injury
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4666908A (en) 1985-04-05 1987-05-19 Warner-Lambert Company 5-Substituted pyrazolo[4,3-d]pyrimidine-7-ones and methods of use
NZ238609A (en) 1990-06-21 1993-12-23 Schering Corp Polycyclic guanine derivatives; preparation, pharmaceutical compositions,
US5202328A (en) 1991-03-06 1993-04-13 Merck & Co., Inc. Substituted fused pyrimidinones
US5294612A (en) 1992-03-30 1994-03-15 Sterling Winthrop Inc. 6-heterocyclyl pyrazolo [3,4-d]pyrimidin-4-ones and compositions and method of use thereof
CA2156918A1 (fr) 1993-02-26 1994-09-01 Deen Tulshian Derives 2-benzylpolycycliques de guanine; methode de preparation
GB9315017D0 (en) 1993-07-20 1993-09-01 Glaxo Lab Sa Chemical compounds
US5824683A (en) 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
SE9701398D0 (sv) 1997-04-15 1997-04-15 Astra Pharma Prod Novel compounds
IT1291372B1 (it) 1997-05-21 1999-01-07 Schering Plough S P A Uso di analoghi eterociclici di 1,2,4-triazolo (1,5-c) pirimidine per la preparazione di medicamenti utili per il trattamento delle malattie
US6013621A (en) 1997-10-17 2000-01-11 The Rockfeller University Method of treating psychosis and/or hyperactivity
GB9722520D0 (en) 1997-10-24 1997-12-24 Pfizer Ltd Compounds
US6133273A (en) 1998-05-08 2000-10-17 American Home Products Corporation Pyrazolopyrimidine-2,4-dione sulfonamides
DE19931206A1 (de) 1999-07-07 2001-01-11 Stief Christian Arzneimittel zur Erhöhung des cAMP-Spiegels und deren Verwendung
HUP0202678A3 (en) 1999-09-30 2004-06-28 Pfizer Certain alkylene diamine-substituted pyrazolo[1,5,-a]-1,5-pyrimidines and pyrazolo[1,5-a]-1,3,5-triazines, pharmaceutical compositions containing them and their use
TWI265925B (en) 1999-10-11 2006-11-11 Pfizer Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
CZ20021151A3 (cs) 1999-10-11 2003-03-12 Pfizer Inc. 5-(2-substituovaný-5-heterocyklylsulfonylpyrid-3-yl)-dihydropyrazolo[4,3-d]-pyrimidin-7-ony jako inhibitory fosfodiesterasy
IL152925A (en) 1999-10-21 2010-04-15 Pfizer Pharmaceutical preparations for the treatment of neurological disease containing an inhibitor of ring guanizine '3', 5 '- monophosphate phosphodiesterase 5 and one of gabapentin or pregabalin
MY125533A (en) 1999-12-06 2006-08-30 Bristol Myers Squibb Co Heterocyclic dihydropyrimidine compounds
JP2004500425A (ja) 2000-04-19 2004-01-08 リリー　アイコス　リミテッド　ライアビリティ　カンパニー パーキンソン病の処置に対する環状ｇｍｐ特異的ホスホジエステラーゼインヒビターの使用
JP2004527510A (ja) 2001-03-16 2004-09-09 ファイザー インコーポレイテッド ＣＧＭＰＰＤＥ阻害剤としてのピラゾロ［４，３−ｄ］ピリミジノン化合物
WO2002088079A2 (fr) * 2001-05-01 2002-11-07 Bristol-Myers Squibb Company Inhibiteurs doubles de pde 7 et pde 4
SE0102315D0 (sv) 2001-06-28 2001-06-28 Astrazeneca Ab Compounds
CA2457944C (fr) 2001-08-28 2009-09-29 Schering Corporation Inhibiteurs polycycliques de la phosphodiesterase v de la guanine
JP2005511500A (ja) 2001-08-31 2005-04-28 ザ ロックフェラー ユニバーシティー 脳におけるホスホジエステラーゼ活性およびホスホジエステラーゼ１ｂ媒介シグナル伝達の調節
WO2003042216A1 (fr) 2001-11-09 2003-05-22 Schering Corporation Inhibiteurs de la phosphodiesterase v de derives polycycliques de guanine
WO2003072801A2 (fr) 2002-02-21 2003-09-04 The Rockefeller University Compositions et methodes de regulation de la signalisation dependant du calcium dans le cerveau
GB0230045D0 (en) 2002-12-23 2003-01-29 Glaxo Group Ltd Compounds
WO2004087906A1 (fr) 2003-03-31 2004-10-14 Pfizer Products Inc. Structure cristalline de 3',5'-phosphodiesterase nucleotidique cyclique 1d(pde1b) et ses utilisations
BRPI0409229A (pt) 2003-04-01 2006-03-28 Applied Research Systems inibidores das fosfodiesterases na infertilidade
EP1680424A2 (fr) 2003-09-05 2006-07-19 Neurogen Corporation Pyridines, pyrazines et pyrimidines fusionnees avec heteroaryle utilisees comme ligands de recepteurs crf1
KR20140022114A (ko) * 2005-06-06 2014-02-21 다케다 야쿠힌 고교 가부시키가이샤 유기 화합물
US20080194592A1 (en) 2005-08-23 2008-08-14 Intra-Cellular Therapies, Inc. Organic Compounds
AU2007256633B2 (en) 2006-06-06 2013-09-12 Intra-Cellular Therapies, Inc. Organic compounds
US20070286890A1 (en) * 2006-06-07 2007-12-13 John Garnett Walt Eyelash applicator and method
EP2081431B1 (fr) 2006-11-13 2013-01-16 Intra-Cellular Therapies, Inc. Composés organiques
JP5837278B2 (ja) 2006-12-05 2015-12-24 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 新規使用
EP2240490B1 (fr) 2007-12-06 2013-09-04 Takeda Pharmaceutical Company Limited Composés organiques
WO2009073210A1 (fr) 2007-12-06 2009-06-11 Intra-Cellular Therapies, Inc Composés organiques
PE20110834A1 (es) 2008-12-06 2011-12-14 Intra Cellular Therapies Inc DERIVADOS DE PIRROL[3,4-d]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1)
EA201170773A1 (ru) 2008-12-06 2012-01-30 Интра-Селлулар Терапиз, Инк. Органические соединения
SG171775A1 (en) * 2008-12-06 2011-07-28 Intra Cellular Therapies Inc Organic compounds
EP2358204B1 (fr) 2008-12-06 2015-08-05 Intra-Cellular Therapies, Inc. Composés de 4,5,7,8-tétrahydro-4-oxo-2H-imidazo[1,2-a]pyrrolo[3,4-e]pyrimidine comme inhibiteurs de PDE1.
JP5813511B2 (ja) 2008-12-06 2015-11-17 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
PE20120209A1 (es) 2008-12-06 2012-03-18 Intra Cellular Therapies Inc DERIVADOS DE IMIDAZO-[1,2-a]-PIRAZOLO [4,3-e]PIRIMIDINA O PIRIMIDO-[1,2-a]-PIRAZOLO [4,3-e]PIRIMIDINA COMO INHIBIDORES DE FOSFODIESTERASA 1 (PDE1)
US11464781B2 (en) 2009-02-25 2022-10-11 Intra-Cellular Therapies, Inc. PDE1 inhibitors for ophthalmic disorders
US9468637B2 (en) 2009-05-13 2016-10-18 Intra-Cellular Therapies, Inc. Organic compounds
JP2013507360A (ja) 2009-10-08 2013-03-04 イントラ−セルラー・セラピーズ・インコーポレイテッド ホスホジエステラーゼ１−標的トレーサーおよび方法
US9434730B2 (en) 2010-05-31 2016-09-06 Intra-Cellular Therapies, Inc. PDE1 inhibitor compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
JP5911854B2 (ja) 2010-05-31 2016-04-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
JP6051210B2 (ja) * 2011-06-10 2016-12-27 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物

Also Published As

Publication number Publication date
CA2740391A1 (fr) 2010-06-10
EP2367429B1 (fr) 2017-06-07
TN2011000246A1 (en) 2012-12-17
KR20110095881A (ko) 2011-08-25
JP5778582B2 (ja) 2015-09-16
EP2367429A1 (fr) 2011-09-28
AU2009322901A1 (en) 2010-06-10
ES2638912T3 (es) 2017-10-24
ECSP11011184A (es) 2011-10-31
CN102231953A (zh) 2011-11-02
ZA201103631B (en) 2013-05-29
IL213314A0 (en) 2011-07-31
PE20110922A1 (es) 2012-01-22
BRPI0922348A2 (pt) 2015-08-11
JP2012510993A (ja) 2012-05-17
US20160083390A1 (en) 2016-03-24
WO2010065149A1 (fr) 2010-06-10
DOP2011000173A (es) 2011-10-31
EP2367429A4 (fr) 2012-06-06
CO6390083A2 (es) 2012-02-29
CL2011001263A1 (es) 2011-11-18
SG171775A1 (en) 2011-07-28
US20150038474A1 (en) 2015-02-05
EA201170770A1 (ru) 2012-02-28
US8536159B2 (en) 2013-09-17
CR20110312A (es) 2011-10-28
US20110245214A1 (en) 2011-10-06
MX2011005933A (es) 2011-12-16
US20140005155A1 (en) 2014-01-02

Similar Documents

Publication Publication Date Title
MA32938B1 (fr) Composes organiques
MA32939B1 (fr) Composes organiques
MA32937B1 (fr) Composes organiques
CR20130045A (es) Compuestos terapéuticos
CR20120295A (es) Triazolopiridinas
BRPI0922351A2 (pt) compostos orgânicos
BRPI0922700A2 (pt) Compostos orgânicos
BRPI0922808A2 (pt) compostos orgânicos
BRPI0914698A2 (pt) compostos orgânicos
BRPI0913966A2 (pt) compostos orgânicos
BRPI0909417A2 (pt) compostos orgânicos
BRPI0915018A2 (pt) compostos orgânicos
DK2310359T3 (da) Organiske forbindelser
BRPI0921826A2 (pt) compostos orgânicos
DK2288375T3 (da) Pegylerede insulin-lispro-forbindelser
BRPI0920707A2 (pt) compostos
BRPI0917574A2 (pt) compostos orgânicos
DK2242759T3 (da) Forbindelser
CR20120297A (es) Espironucleósidos uracílicos oxetánicos
BRPI0907611A2 (pt) Compostos orgânicos
ME01665B (me) Analozi buprenorfina
BRPI0914775A2 (pt) compostos de fenila dissubstituídos
DK2323972T3 (da) C7-fluor-substituerede tetracylinforbindelser
DK2297162T3 (da) Forbindelser
UY31688A1 (es) Plaguicidas